TY - JOUR
T1 - Comparison of the immunogenicity and safety of polysaccharide and protein-conjugated pneumococcal vaccines among the elderly aged 80 years or older in Japan
T2 - An open-labeled randomized study
AU - Namkoong, Ho
AU - Funatsu, Yohei
AU - Oishi, Kazunori
AU - Akeda, Yukihiro
AU - Hiraoka, Rika
AU - Takeshita, Kei
AU - Asami, Takahiro
AU - Yagi, Kazuma
AU - Kimizuka, Yoshifumi
AU - Ishii, Makoto
AU - Tasaka, Sadatomo
AU - Suzuki, Yukio
AU - Iwata, Satoshi
AU - Betsuyaku, Tomoko
AU - Hasegawa, Naoki
N1 - Funding Information:
The authors are grateful to Yamamoto M, Hattori Y, and Hayakawa M for technical assistance, and to Uemura Y for analyzing the clinical and laboratory data. This work was supported by research grants from the Ministry of Health, Labor, and Welfare of Japan ( 24170201 ).
PY - 2015/1/3
Y1 - 2015/1/3
N2 - An open-labeled randomized study was conducted to compare the immunogenicity and safety of polysaccharide (PPV23) or protein-conjugated pneumococcal vaccine (PCV7) among the elderly aged 80 years or older. A total of 105 nursing home residents were enrolled in this study. We analyzed the geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) and the geometric mean titer (GMT) of the opsonization index (OI) for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. The GMCs of serotype-specific IgG and the GMTs of the OI significantly increased one month after vaccination in both groups for all seven serotypes evaluated. In the PCV7 group, study subjects with serotypes 4, 9V, 18C, and 23F exhibited statistically significant elevations in both serotype-specific IgGs and OIs compared to those of the PPV23 group. Both vaccines were tolerated without any severe adverse events, and no differences in systemic adverse events were observed between the two groups, although adverse reactions such as redness and localized swelling were more common in the PCV7 group. Our data demonstrated that the GMCs of serotype-specific IgG and the GMTs of the OI were higher in the PCV7 group compared to those in the PPV23 group. Our study also confirmed the safety of both the PCV7 and PPV23 vaccines in elderly people aged 80 years or older.
AB - An open-labeled randomized study was conducted to compare the immunogenicity and safety of polysaccharide (PPV23) or protein-conjugated pneumococcal vaccine (PCV7) among the elderly aged 80 years or older. A total of 105 nursing home residents were enrolled in this study. We analyzed the geometric mean concentration (GMC) of serotype-specific immunoglobulin G (IgG) and the geometric mean titer (GMT) of the opsonization index (OI) for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. The GMCs of serotype-specific IgG and the GMTs of the OI significantly increased one month after vaccination in both groups for all seven serotypes evaluated. In the PCV7 group, study subjects with serotypes 4, 9V, 18C, and 23F exhibited statistically significant elevations in both serotype-specific IgGs and OIs compared to those of the PPV23 group. Both vaccines were tolerated without any severe adverse events, and no differences in systemic adverse events were observed between the two groups, although adverse reactions such as redness and localized swelling were more common in the PCV7 group. Our data demonstrated that the GMCs of serotype-specific IgG and the GMTs of the OI were higher in the PCV7 group compared to those in the PPV23 group. Our study also confirmed the safety of both the PCV7 and PPV23 vaccines in elderly people aged 80 years or older.
KW - Elderly patients
KW - Pneumococcal polysaccharide vaccine
KW - Pneumococcal protein-conjugate vaccine
KW - Serotype-specific IgG
KW - Serotype-specific opsonophagocytic activity
UR - http://www.scopus.com/inward/record.url?scp=84922347367&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84922347367&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2014.11.023
DO - 10.1016/j.vaccine.2014.11.023
M3 - Article
C2 - 25448102
AN - SCOPUS:84922347367
VL - 33
SP - 327
EP - 332
JO - Vaccine
JF - Vaccine
SN - 0264-410X
IS - 2
ER -